Loading
A phase 3 trial of dostarlimab in colorectal cancer, run by GlaxoSmithKline, not yet recruiting.
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer is a phase 3, interventional study registered as NCT07740720 by GlaxoSmithKline, with a registry enrolment figure of 90 participants, started 2026-09-17 and due to reach its primary completion in 2029-12-12. Interventions recorded: Dostarlimab. Conditions listed: Neoplasms, Rectal. Primary outcome: Percentage of participants who achieve clinical complete response (cCR) amongst participants who receive > 9 cycles (> 6 months) of dostarlimab monotherapy by investigator assessment. Colorectal eligibility wording from the registry: "* Has histologically confirmed Stage II to III (T3-T4, N0, or T any, N+) locally advanced rectal adenocarcinoma". No results are recorded here; the registry entry is the source.
Shares Dostarlimab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Dostarlimab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Dostarlimab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.